<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39309490</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2211-3835</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Acta pharmaceutica Sinica. B</Title><ISOAbbreviation>Acta Pharm Sin B</ISOAbbreviation></Journal><ArticleTitle>Jun12682, a potent SARS-CoV-2 papain-like protease inhibitor with exceptional antiviral efficacy in mice.</ArticleTitle><Pagination><StartPage>4189</StartPage><EndPage>4192</EndPage><MedlinePgn>4189-4192</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.apsb.2024.07.001</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Mianling</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Ji'nan 250012, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Meehyein</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Therapeutic Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Ji'nan 250012, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Acta Pharm Sin B</MedlineTA><NlmUniqueID>101600560</NlmUniqueID><ISSNLinking>2211-3835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-drug resistance</Keyword><Keyword MajorTopicYN="N">Broad-spectrum</Keyword><Keyword MajorTopicYN="N">Drug candidate</Keyword><Keyword MajorTopicYN="N">Papain-like protease</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39309490</ArticleId><ArticleId IdType="pmc">PMC11413657</ArticleId><ArticleId IdType="doi">10.1016/j.apsb.2024.07.001</ArticleId><ArticleId IdType="pii">S2211-3835(24)00261-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tan B., Zhang X., Ansari A., Jadhav P., Tan H., Li K., et al. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science. 2024;383:1434–1440.</Citation><ArticleIdList><ArticleId IdType="pubmed">38547259</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin R. As COVID-19 cases surge, here's what to know aabout JN.1, the latest SARS-CoV-2 "variant of interest". JAMA. 2024;331:382–383.</Citation><ArticleIdList><ArticleId IdType="pubmed">38214935</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L., Gao S., Ye B., Yang M., Cheng Y., Kang D., et al. Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors. Acta Pharm Sin B. 2024;14:87–109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10792984</ArticleId><ArticleId IdType="pubmed">38239241</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman N.S., Bucris E., Keidar-Friedman D., Amsalem M., Brosh-Nissimov T. Nirmatrelvir resistance-de Novo E166V/L50V mutations in an immunocompromised patient treated with prolonged Nirmatrelvir/Ritonavir monotherapy leading to clinical and virological treatment failure‒a case report. Clin Infect Dis. 2024;78:352–355.</Citation><ArticleIdList><ArticleId IdType="pubmed">37596935</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A., et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;587:657–662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116779</ArticleId><ArticleId IdType="pubmed">32726803</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Z., Ratia K., Cooper L., Kong D., Lee H., Kwon Y., et al. Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity. J Med Chem. 2022;65:2940–2955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8547495</ArticleId><ArticleId IdType="pubmed">34665619</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan H., Hu Y., Jadhav P., Tan B., Wang J. Progress and challenges in targeting the SARS-CoV-2 papain-like protease. J Med Chem. 2022;65:7561–7580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9159073</ArticleId><ArticleId IdType="pubmed">35620927</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D., Duan L., Huang B., Xiong Y., Zhang G., Huang H. The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING. Sci Signal. 2023;16</Citation><ArticleIdList><ArticleId IdType="pubmed">37130168</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>